RecruitingPHASE1, PHASE2NCT06780111
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Studying Squamous cell carcinoma of the esophagus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Pembrolizumab(biological)
- Enrollment
- 298 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2032
Study locations (30)
- UPMC Hillman Cancer Center ( Site 1904), Pittsburgh, Pennsylvania, United States
- Liga Norte Riograndense Contra o Cancer ( Site 1301), Natal, Rio Grande do Norte, Brazil
- Hospital Nossa Senhora da Conceicao ( Site 1300), Porto Alegre, Rio Grande do Sul, Brazil
- Clínica Puerto Montt ( Site 1406), Port Montt, Los Lagos Region, Chile
- FALP ( Site 1400), Santiago, Region M. de Santiago, Chile
- Centro de Oncología de Precisión ( Site 1402), Santiago, Region M. de Santiago, Chile
- Clínica UC San Carlos de Apoquindo ( Site 1403), Santiago, Region M. de Santiago, Chile
- Bradfordhill ( Site 1401), Santiago, Region M. de Santiago, Chile
- Bradford Hill Norte ( Site 1405), Antofagasta, Chile
- The Second Affiliated Hospital of Anhui Medical University ( Site 9511), Hefei, Anhui, China
- Beijing Cancer Hospital ( Site 9500), Beijing, Beijing Municipality, China
- The First Affiliated Hospital of Xiamen University ( Site 9503), Xiamen, Fujian, China
- Henan Cancer Hospital ( Site 9509), Zhengzhou, Henan, China
- Xuzhou Central Hospital ( Site 9512), Xuzhou, Jiangsu, China
- The First Affiliated Hospital of Nanchang University ( Site 9505), Nanchang, Jiangxi, China
- +15 more locations on ClinicalTrials.gov
Collaborators
Daiichi Sankyo
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06780111 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the esophagus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07457528Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCCTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07331155A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]Nanjing Leads Biolabs Co.,Ltd
- RECRUITINGPHASE1NCT07503808A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesIDEAYA Biosciences
- RECRUITINGPHASE2NCT07403136Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCCFudan University
- RECRUITINGPHASE1, PHASE2NCT07385001A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCCTang-Du Hospital
- RECRUITINGPHASE2NCT07263919Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)Akeso
- RECRUITINGPHASE2NCT07481058KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal CancerBeijing Konruns Pharmaceutical Co., Ltd.
- RECRUITINGPHASE1NCT07217171A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasEvolveImmune United, Inc
See all trials for Squamous cell carcinoma of the esophagus →